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Background: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease leading to the death of
affected individuals within years. The involvement of inflammation in the pathogenesis of neurodegenerative
diseases, including ALS, is increasingly recognized but still not well understood. The aim of this study is to evaluate
the levels of inflammation-related IL-1 family cytokines (IL-1β, IL-18, IL-33, IL-37) and their endogenous inhibitors
(IL-1Ra, sIL-1R2, IL-18BP, sIL-1R4) in patients with sporadic ALS (sALS),
Methods: Sera were collected from 144 patients (125 patients were characterized by disease form, duration, and
disability, using the revised ALS functional rating scale (ALSFRS-R) and from 40 matched controls. Cerebrospinal
fluid (CSF) was collected from 54 patients with sALS and 65 patients with other non-infectious non-oncogenic
diseases as controls. Cytokines and inhibitors were measured by commercial ELISA.
Results: Among the IL-1 family cytokines tested total IL-18, its endogenous inhibitor IL-18BP, and the active form of
the cytokine (free IL-18) were significantly higher in the sALS sera than in controls. No correlation between these
soluble mediators and different clinical forms of sALS or the clinical setting of the disease was found. IL-18BP was
the only mediator detectable in the CSF of patients.
Conclusions: Among the IL-1 family cytokines, only IL-18 correlates with this disease and may therefore have a
pathological role in sALS. The increase of total IL-18 suggests the activation of IL-18-cleaving inflammasome.
Whether IL-18 upregulation in circulation of sALS patients is a consequence of inflammation or one of the
causes of the pathology still needs to be addressed.
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Amyotrophic lateral sclerosis (ALS) is a fatal neuromus-
cular disorder characterized by the progressive loss of
anterior-lateral horn spinal cord motoneurons, leading
to progressive muscular weakness and eventual death of
affected individuals [1]. Sporadic ALS (sALS) is the primary
form of the disease, affecting 95% of ALS patients, while
the remaining 5% of cases have a familial form of the
disease.
Several studies have suggested that immune activation
and inflammatory mechanisms may have an active role* Correspondence: d.boraschi@ibp.cnr.it
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unless otherwise stated.in ALS pathogenesis [2]. It has been reported that pa-
tients with sALS exhibit an anomalous monocyte pheno-
type, with increased expression of CD16 and HLA-class
II, which is directly related to the rate of sALS disease
progression [3]. Infiltrating macrophages and T cells
have been found in the central nervous system (CNS) in
human ALS, and immunoglobulin G (IgG) and comple-
ment deposition are also evident [2,4-6]. Parallel to cell
infiltration, increased levels of pro-inflammatory cyto-
kines such as CCL2 [7] and IL-6 have been reported in
both the cerebrospinal fluid (CSF) [8] and sera [9], and
increased levels of TNF-α were detected in the blood of
these patients [10].
An involvement of IL-1 family cytokines in the path-
ology of ALS has been suggested by the finding of acti-
vated caspase-1 and increased IL-1β both in ALS mouseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and clinical characteristics of sALS
patients
sALS patients (total) 125
Sex (F/M) 69/56
Age (mean and range) 63.28 (32–82)
Disease duration (in months; mean and range) 11.32 (1–48)
ALSFRS-R (mean and range) 44 (35–48)
Bulbar (n/total) 22/125
Upper limb (n/total) 45/125
Lower limb (n/total) 58/125
sALS, sporadic amyotrophic lateral sclerosis, ALSFRS-R, revised ALS functional
rating scale. Bulbar, upper limb, lower limb is a clinical classification based on
involved body areas at the onset of disease. Cases with only bulbar signs or
symptoms for the first three months from onset, with spinal symptoms or
signs occurring later, are considered bulbar onset ALS. Cases in which any
spinal symptoms or signs appeared in the first three months are considered
spinal onset ALS (either upper or lower limb).
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eight cytokines with inflammatory or anti-inflammatory
activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ,
IL-37), and three receptor antagonists (IL-1Ra, IL-36Ra,
IL-38) [14,15]. Members of the IL-1 receptor (IL-1R) fam-
ily include four receptor chains and two accessory chains
that form four signalling complexes, two orphan recep-
tors, two decoy receptors (IL-1R2, IL-18BP), and two
negative regulators [16].
IL-1β and IL-18 are synthesized as biologically inactive
precursors and subsequently cleaved by caspase-1 to give rise
to mature active cytokines [17]. Also the anti-inflammatory
cytokine IL-37 is synthesized as a long protein, which needs
caspase-1 both for its nuclear translocation (where it may act
as a DNA-binding protein) and for its cleavage and extracel-
lular release as an IL-1-like cytokine [18]. IL-1β exerts its
potent inflammatory effect by binding to IL-1R1, and its
activity is inhibited by the IL-1R antagonist IL-1Ra, which
competes with IL-1β for IL-1R1 binding. IL-1R2 functions as
a decoy receptor for IL-1β, capturing the cytokine and pre-
venting its interaction with IL-1R1 [16,19].
IL-18 is cytokine strongly involved in type 1 inflamma-
tion, as it induces activation of Th1 cells and production
of IFN-γ by Th1 and NK cells [20]. IL-18 is produced by
many cell types, including leukocytes, epithelial and
endothelial cells, and various cells of the adipose tissue.
The inflammation-related effects of IL-18 may vary de-
pending on the microenvironment, and there are reports
suggesting that IL-18 could also be involved in type 2 in-
flammation and Th2 cell activation [21]. Beside inflam-
matory effects, IL-18 is also involved in regulating energy
homeostasis (by controlling food intake, energy expend-
iture and respiratory exchange) [22,23] and in maintaining
the functional integrity of mucosal barrier functions [24].
IL-18 is regulated by the IL-18 binding protein (IL-18BP),
a soluble molecule that binds mature IL-18 with high
affinity and prevents its interaction with cell surface
receptors. Only the fraction of IL-18 that is not bound to
IL-18BP is actually free to interact with the membrane
receptors on target cells/organs and is biologically active.
Also the anti-inflammatory cytokine IL-37, in its caspase-
1-dependent extracellular short form, binds to IL-18 recep-
tors and is inhibited by IL-18BP [14,25]. IL-33 is another
member of IL-1 family highly homologous to IL-18 [26].
IL-33 is synthesized as a pro-protein that acts as nuclear
factor regulating transcription. Upon inflammasome- and
caspase-1-independent cleavage, mature IL-33 is exported
extracellularly and acts as a cytokine by binding to its
receptor IL-1R4 (previously known as T1/ST2), thereby
recruiting and activating leukocytes and inducing Th2-
associated cytokines [27]. The soluble form of the receptor,
sIL-1R4, is a natural inhibitor of IL-33.
In order to investigate if the IL-1 network and inflam-
masome hyperactivation have a pathogenic role in sALSby promoting neuroinflammation and contributing to
disease progression, we analyzed the levels of IL-1 family
molecules (IL-1β, IL-18, IL-33, IL-37) and their en-
dogenous inhibitors (IL-1Ra, sIL-1R2, IL-18BP, sIL-1R4)
in serum and CSF from sALS patients.
Methods
Subjects
A total of 144 ALS patients were included in the study.
Clinical data at the time of blood and CSF drawing were
available for 125 patients (Table 1). CSF was collected in
54 patients out of 144.
To evaluate overall patient functional status, the Re-
vised ALS Functional Rating Scale (ALSFRS-R, scored
0–48) was used [28]. All patients had ALS with a range
of ALSFRS-R scores of between 35 and 48. Disease on-
set had occurred in patients between 1 and 96 months
before the time of sampling. A total of 40 healthy serum
donors (30 females and 10 males, mean age 51 ± 19
years), and 65 CSF donors (37 females and 28 males,
mean age 56 ± 20 years) with different kinds of non-
infectious non-inflammatory pathologies were used as
controls. Written informed consent was obtained from
all subjects. The study was approved by the local Ethics
Committees.
Cytokine assay in serum and CSF
Cytokine levels in serum and CSF were measured by
ELISA with commercially available assays. The ELISA
kit for human IL-18 was obtained from MBL (Woburn,
Massachusetts, United States), kits for hIL-18BPa, hIL-
1β, hIL-1Ra, hsIL-1R2, hIL-33, and hsIL-1R4 were pur-
chased from R&D Systems Inc. (Minneapolis, New
Mexico, United States), while the ELISA kit for hIL-37
was provided by AdipoGen, Inc. (Seoul, South Korea).
The IL-18 kit from MBL could detect total IL-18 (either
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Results obtained with the IL-18BPa ELISA were adjusted
by considering the different molecular weight of the
standard (a chimeric protein), as already described [30].
The concentration of free IL-18 (biologically active cyto-
kine not bound by its inhibitor) was calculated as previ-
ously described [30], by applying the law of mass action
to the measured concentrations of IL-18 and IL-18BP,
considering that the interaction between the two factors
is 1:1 and that the Kd of their binding is 400 pM [31].
Statistical analysis
Analysis of the data was performed using the Mann–
Whitney U-test. Spearman’s rank correlation analysis
was used to correlate disease activity score and serum
levels of cytokines (total IL-18, IL-18BP and free IL-18).
A P value of less than 0.05 was considered statistically
significant.
Results
IL-1β was undetectable in the serum of sALS patients,
with the exception of one ALS patient that had measur-
able circulating IL-1β (Table 2). At variance with IL-1,
IL-18 was measurable in sera and its levels were signifi-
cantly increased in sALS compared to normal healthy
subjects (NHS) (P <0.0001, Figure 1A). The soluble in-
hibitor of IL-18, IL-18BP, was similarly increased in the
serum of sALS patients as compared to NHS (P <0.0001,
Figure 1B). Despite the increase in IL-18BP, serum levels
of free IL-18 were still significantly higher in ALS patients
than in NHS controls (P = 0.0171, Figure 1C).
IL-1β and IL-18 were not detectable in the CSF of
sALS patients or healthy and disease controls (patients
with non-infectious non-inflammatory neurological dis-
eases) (Table 2). IL-18BP was detected in the CSF of
sALS patients (mean ± SD: 99 ± 67 pM) as well as in dis-
ease controls (91 ± 69 pM) and in healthy controls (156
± 116 pM), but these differences were not statistically




IL-1Ra <78.1 <78.1 (n
sIL-1R2 <312.5 <312.5 (
IL-33 <30.0 (n = 3; 72.9 ± 32.3) <30.0 (n =
sIL-1R4 <62.5 (n = 4; 85.1 ± 13.2) <62.5(n =
IL-37 <46.8 <
IL-36 NT
Values are given as mean pg/ml ± SD rather than in nM since the MW of the matur
precisely defined.
CSF, Cerebrospinal fluid; n, Number of samples above the detection limit; NT, Not tserum and CSF was evaluated. IL-1Ra was not detectable
in NHS sera; IL-1Ra was only detected (547 pg/ml) in
the serum of the one sALS patient who had measurable
IL-1β. In CSF, IL-1Ra was found only in one control
(102 pg/ml), without obvious correlation with disease
state. The other IL-1 inhibitor, the soluble form of the
IL-1R2 (sIL-1R2), was present in sera of sALS patients
in amounts similar to controls (Table 2). In CSF, sIL-1R2
was detectable in one healthy control only (326 pg/ml).
IL-33 and sIL-1R4 levels were comparable in sALS and
normal sera. In CSF, the cytokine and its soluble receptor
were undetectable, with the exception of a few patients
and controls (Table 2).
Another important inhibitor of inflammation that has
been recently described is IL-37, a cytokine of the IL-1
family structurally very similar to IL-1 and IL-18, and al-
legedly able to bind to IL-18BP [32]. The most abundant
isoform of the cytokine, IL-37b, was undetectable in the
CSF and serum of both sALS patients and controls
(Table 2). We then analyzed the relationship between
cytokine levels and clinical parameters of the disease.
Free serum IL-18 (as well as total IL-18 and IL-18BP)
did not significantly correlate with the ALSFRS-R score,
nor with the time from diagnosis (data not shown).
When patients were subdivided according to clinical
presentation in bulbar, upper limbs and lower limbs
form, total IL-18 and IL-18BP serum levels were signi-
ficantly higher in each subgroup compared to NHS
(Figure 1A and B). Free IL-18 was significantly increased
in lower limbs form with respect to controls (Figure 1C).
Discussion
The data collected in the current study shows that,
among the cytokines of the IL-1 family tested, only
IL-18 and IL-18BP are increased in the serum of sALS
patients. Measuring both the active cytokine and its in-
hibitor in serum is required in order to correctly evaluate
the net biological effects, as only free IL-18, not captured
by its inhibitor, is able to exert its biological effects [31]. Itrum of sALS patients
Serum
ntrols ALS Controls
<7.8 <7.8 (n = 1; 47.2) <7.8 (n = 1; 26.6)
= 1; 101.7) <78.1 (n = 1; 547.4) <78.1
n = 1; 325.7) 5673.4 ± 2771.5 5575.0 ± 1359.5
3; 54.8 ± 27.1) 625.4 ± 1570.5 536.3 ± 1166.3
2; 85.5 ± 3.9) 72.4 ± 16.4 79.9 ± 28.3
46.8 <46.8 <46.8 (n = 1; 74.7)
NT 888.3 ± 729.3 1531.7 ± 1843.2
e forms of the cytokines and of the natural soluble receptors are not yet
ested; sALS, sporadic amyotrophic lateral sclerosis.
Figure 1 Levels of IL-18, IL-18BP and free IL-18 in serum of ALS
patients. Levels of IL-18 (A) and of IL-18BP (B) were measured by
ELISA in sera from sporadic ALS patients (sALS) in comparison to
NHS. Patients were also grouped depending on the form of the
disease. Based on the law of mass action, the concentration of free
IL-18 (not bound and inhibited by IL-18BP) was calculated from
total IL-18 and total IL-18BP concentrations [30,31] (C). Statistical
significance was calculated using the Mann–Whitney U-test. ALS,
amyotrophic lateral sclerosis; BF, bulbar form; LL, lower limbs; NHS,
normal healthy subjects; UL, upper limbs.
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is not sufficient for full inhibition of the active cytokine
because inhibition efficiency depends both on the kinetics
of association and dissociation between the two molecules,
and on the actual concentration of IL-18 and IL-18BP in
serum rather than on their ratio. Thus, despite the over-
production of IL-18BP in these patients, it is nevertheless
insufficient for controlling the excessive production of
IL-18. As a consequence, free active IL-18 is significantly
higher in sALS patients than in healthy individuals.
Whether this increase in the active cytokine levels may
have a pathological significance is not known. Increased
IL-18 levels are associated with a variety of diseases and,
in general, to ongoing inflammation. High levels of circu-
lating IL-18 are found also in mild inflammatory condi-
tions such as in the elderly or in obese individuals [33-35].
In addition, IL-18 can have either protective or detrimen-
tal effects depending on the tissue microenvironmental
conditions, for instance in the regulation of allergic reac-
tions [36] or in the protection versus destruction of the
mucosal tissue [24,37,38].
High concentrations of circulating IL-18 may suggest
the involvement of inflammasome-dependent inflamma-
tion in the disease. The inflammasome, a cytosolic mo-
lecular complex that controls the activation of caspase-1
[39], is a key component of the inflammatory machinery.
Once activated, caspase-1 processes pro-IL-1β and pro-
IL-18, two inflammatory cytokines that require cleavage
in order to attain their active forms. The levels of IL-18
can provide information of inflammasome activation and
local IL-1β production, since circulating IL-1β is detect-
able only in extreme or fatal situations of shock due to
its potent bioactivity. On the other hand, IL-18, which is
much less dangerous than IL-1β as it has not vasoactive
effects, can be found at detectable levels in the serum of
normal subjects and it increases in pathological and
inflammatory conditions, thus acting as a sign of an
ongoing inflammasome-related inflammation.
In the SOD1-G93A mouse model of ALS, the disease
is caused by a mutation in superoxide dismutase 1
(SOD1) that provokes enhanced inflammation and the
production of a broad spectrum of inflammatory cyto-
kines [40-42]. Active caspase-1 is a marker of inflamma-
tion in the CNS of SOD1-G93A mice [11,12]. Indeed,
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levels of caspase-1 activation and concomitant increase
in the secretion of mature IL-1β [1]. SOD1 mutations
are the most common genetic cause of ALS in humans
(accounting for 20% of familial ALS cases) [43], although
in about 95% of ALS patients no genetic cause can be
identified (sALS patients) [44].
In mouse models and in familial ALS patients, activa-
tion of caspase-1 has been detected in spinal cords and,
consequently, mature IL-1β levels were higher in spinal
cord samples [11,12]. Thus, the present study suggests
that caspase-1 activation may also be involved in the
pathogenesis of sALS, in which the SOD1 mutation is
not present.
According to our data, IL-18 and IL-1β are not detect-
able in CSF, suggesting a predominantly tissue-restricted
activity of the inflammatory cytokines. On the contrary,
IL-18BP is present in CSF, but it does not seems to be
associated to the disease since its levels are comparable
between healthy or disease controls and sALS patients.
Another ligand of IL-18BP that is also able to bind the
alpha chain of the IL-18 receptor is IL-37, a cytokine
that down-regulates inflammation by inhibiting the gene
expression of a range of inflammatory cytokines [25,45].
IL-37 increases in response to inflammatory stimulation,
probably acting as a self-regulator of the defensive in-
flammatory reaction [25,45], and its presence has been
observed in several inflammatory disease conditions (for
example in the mucosa of patients with Crohn’s disease)
[46]. IL-37 was not detected in the serum or CSF from
sALS patients or controls. In the absence of measurable
levels of known IL-18BP ligands in the CSF, the high
constitutive levels of IL-18BP may suggest the physio-
logical need to maintain an anti-inflammatory micro-
environment in CNS.
Previous studies suggest that other inflammatory cyto-
kines may play a role in ALS. Increased levels of IL-6
have been observed in CSF and serum of ALS patients
[8,9], and TNF-α was elevated in blood of patients [10].
The chemokine CCL2 (chemoattractant and regulator
of blood–brain barrier permeability [47]) was also in-
creased in the serum and CSF of patients with ALS [48].
On the whole, these data, and our finding of raised
serum levels of free IL-18, support the hypothesis that
inflammatory mechanisms may have an active role in the
disease process of ALS. In addition, our data suggests
that in the sporadic form of the disease inflammasome-
dependent caspase-1 activation may be involved, although
the mechanisms of inflammasome activation would obvi-
ously be different than those in familial ALS. Despite the
fact that IL-1β is not detectable in the circulation, it is
likely that a local increase of this cytokine may occur and
take part in the disease development, whereas the in-
creased levels of circulating IL-18 may be symptomatic ofan ongoing caspase-1-dependent inflammatory reaction
but not directly involved in the pathology. In parallel to
the notion that caspase-1 is activated in sALS, the absence
of circulating IL-1Ra and the unchanged levels of sIL-1R2,
the two inhibitors of IL-1β activity, suggest that IL-1β
would exclusively exert its pathological effects at the local
level. Overall, these results suggest that anti-inflammatory
approaches based on IL-1β inhibition may be beneficial in
treating sALS.
Conclusions
In the sALS patients we studied, IL-18 levels were signifi-
cantly increased, but did not correlate with disease sever-
ity. This suggests a role of the cytokine in the pathological
mechanisms underlying the disease, rather than in disease
progression. Published data from Meissner et al. in the
SOD1-G93A mouse model [13] showed that deficiency in
caspase-1 IL-1β or IL-18 did not modify disease onset,
thus suggesting that caspase-1-dependent inflammation
does not initiate the disease. On the other hand, both
caspase-1 and IL-1β (but not IL-18) deficiency extended
the lifespan of ALS mice, suggesting that IL-1β-dependent
inflammation is involved in the disease process. Thus, cir-
culating IL-18 appears to be a marker of neuroinflamma-
tion, indicating caspase-1 activation and local IL-1β
effects, whereas it does not represent a useful biomarker
in the follow-up of sALS patients.
It is presently unclear if inflammation has a role in ini-
tiating neuronal degeneration in ALS, as demonstrated
for other neurodegenerative diseases, or it rather is the
result of neurodegeneration that then contributes to ex-
acerbate the disease [49-51]. In any case, the experimen-
tal evidence supports the hypothesis that deregulated
inflammatory reactions, in addition to genetic and
environmental factors, could be a key mechanism in
the development of sALS, if not its initiation. This
further suggests that anti-inflammatory treatments,
including inhibition of IL-1β, could be beneficial in
ALS patients.
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